Education
About Us
Working with TipRanks
Follow Us
X4 Pharmaceuticals Inc (XFOR)
NASDAQ:XFOR
XFOR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.35 - $26.84
Previous CloseN/A
Volume769.31K
Average Volume (3M)7.29M
Market Cap
$68.25M
Enterprise Value$29.16M
Total Cash (Recent Filing)$62.95M
Total Debt (Recent Filing)$2.18M
Price to Earnings (P/E)0.7
Beta1.58
Next Earnings
Nov 06, 2025EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.47
Shares Outstanding22,449,133
10 Day Avg. Volume586,435
30 Day Avg. Volume7,286,794
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.43
Enterprise Value/Revenue0.89
Enterprise Value/Gross Profit1.07
Enterprise Value/Ebitda-0.31
Forecast
1Y Price Target
$6.25Price Target Upside105.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Financial HealthThe $60M private placement not only strengthens the company's balance sheet but also aids in meeting loan covenant obligations.
Leadership ChangesThe appointment of new C-suite management and board of directors, including experienced leaders from CTI BioPharma, is expected to strengthen X4 Pharmaceuticals' position.
Revenue PerformanceThe company reported total revenue of $28.8M, compared to the consensus estimate of $11.6M, and a net income of $0.04 per share, compared to the consensus estimated a net loss of $0.12 per share.
Bears Say
Market ChallengesThe analyst is taking a more conservative view of the launch trajectory and commercial opportunity in WHIM syndrome, leading to lowered estimates.
Stock AdjustmentsThe company enacted a reverse stock split effective April 28; accordingly, the price target is adjusted to $7 based on the updated outstanding share count.
X4 Pharmaceuticals News
XFOR FAQ
What was X4 Pharmaceuticals Inc’s price range in the past 12 months?
X4 Pharmaceuticals Inc lowest stock price was $1.35 and its highest was $26.84 in the past 12 months.
What is X4 Pharmaceuticals Inc’s market cap?
X4 Pharmaceuticals Inc’s market cap is $68.25M.
When is X4 Pharmaceuticals Inc’s upcoming earnings report date?
X4 Pharmaceuticals Inc’s upcoming earnings report date is Nov 06, 2025 which is in 48 days.
How were X4 Pharmaceuticals Inc’s earnings last quarter?
X4 Pharmaceuticals Inc released its earnings results on Jul 31, 2025. The company reported -$3.47 earnings per share for the quarter, missing the consensus estimate of -$3.368 by -$0.102.
Is X4 Pharmaceuticals Inc overvalued?
According to Wall Street analysts X4 Pharmaceuticals Inc’s price is currently Undervalued.
Does X4 Pharmaceuticals Inc pay dividends?
X4 Pharmaceuticals Inc does not currently pay dividends.
What is X4 Pharmaceuticals Inc’s EPS estimate?
X4 Pharmaceuticals Inc’s EPS estimate is -0.55.
How many shares outstanding does X4 Pharmaceuticals Inc have?
X4 Pharmaceuticals Inc has 22,449,133 shares outstanding.
What happened to X4 Pharmaceuticals Inc’s price movement after its last earnings report?
X4 Pharmaceuticals Inc reported an EPS of -$3.47 in its last earnings report, missing expectations of -$3.368. Following the earnings report the stock price went down -5.085%.
Which hedge fund is a major shareholder of X4 Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in XFOR
X4 Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.25 (105.59% Upside)
$6.25 (105.59% Upside)
Blogger Sentiment
Bullish
XFOR Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 129.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 12.3%
Last 30 Days ▼ 12.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.58%
12-Months-Change
Fundamentals
Return on Equity
-207.22%
Trailing 12-Months
Asset Growth
-50.07%
Trailing 12-Months
Company Description
X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
XFOR Company Deck
XFOR Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and global expansion efforts, supported by a strong financial position and promising market research. However, challenges remain in sales consistency and the brief commercial history in the WHIM market.View all XFOR earnings summariesXFOR Stock 12 Month Forecast
Average Price Target
$6.25
▲(105.59% Upside)
Technical Analysis
Karyopharm Therapeutics
―
NRX Pharmaceuticals
―
Repare Therapeutics
―
Xilio Therapeutics
―
PepGen Inc.
―
Ownership Overview
33.06% Insiders
3.69% Mutual Funds
4.23% Other Institutional Investors
58.12% Public Companies and
Individual Investors